Cancer Research

Approximately 20 percent of all breast cancer diagnoses are classified as HER2-positive, a subtype historically associated with aggressive growth and poor clinical outcomes. The landscape of HER2-positive early breast cancer treatment has undergone a significant transformation with the European

Incyte Corporation and Genmab A/S have joined forces to launch a Phase 1/2 clinical trial aimed at transforming the treatment landscape for metastatic colorectal cancer patients with the KRAS G12D mutation. This specific genetic alteration has long served as a formidable barrier in oncology, as it

The actionability gap in genomic testing remains a significant hurdle, as physicians frequently identify mutations for which no effective targeted therapies currently exist. This discrepancy underscores a profound shift in modern oncology where the bottleneck is no longer the ability to map the

Radiologists are moving beyond simple diameter measurements to develop quantitative biomarkers that map the underlying cellular and metabolic states of malignant tissues. This fundamental shift marks the end of an era dominated by subjective visual assessments that were often prone to interobserver

Gold nanoparticles demonstrate a unique capacity to absorb near-infrared light and convert it into precise thermal energy capable of destroying malignant cells without damaging all surrounding healthy tissue. This specific characteristic, known as the photothermal effect, has transformed

While 177Lu-PSMA-617 has improved survival, many patients eventually see their cancer progress as the disease develops resistance to beta-particle radiation. This clinical hurdle has forced researchers to look beyond standard therapies toward the high-energy potential of alpha-emitting isotopes.